RxDoctor Payments Data

Michael Allan, MD

Clinical Cardiac Electrophysiology · Fort Oglethorpe, GANPI 1124035571

Payments from drug & device makers

$14,053in general payments, 2019–2025

Across 217 payments — averaging $64.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$7K
  • Boehringer Ingelheim$4K
  • Abbott$1K
  • Biosense Webster, Inc.$241
  • Pfizer$200
  • Lexicon Pharmaceuticals, Inc.$189
  • plus $1K from 20 others
$6,165in research payments, 2019–2025

Across 6 payments — averaging $1027.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boston Scientific$6K

What the payments were for

  • Speaking & faculty fees$6,82049%
  • Travel & lodging$2,95721%
  • Food & beverage$4,27630%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,053 in reported general payments places this provider in the 35th percentile of 93 clinical cardiac electrophysiology providers in Georgia.

See all clinical cardiac electrophysiology providers in Georgia

Medicare billing

Part B allowed, 2024
$270,865
Medicare patients
2,787
Services billed
6,531

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban294$253,411
XareltoRivaroxaban57$47,609
EntrestoSacubitril/Valsartan40$30,867
FarxigaDapagliflozin Propanediol48$30,361
JardianceEmpagliflozin29$17,998
MultaqDronedarone Hcl14$10,524
Propafenone Hcl ErPropafenone Hcl34$7,115
Dabigatran EtexilateDabigatran Etexilate Mesylate32$5,402
Flecainide Acetate87$4,118
Propafenone Hcl91$3,611
Enoxaparin Sodium17$3,341
Digoxin170$2,877
Mexiletine Hcl29$2,819
Dofetilide21$2,245
Metoprolol Succinate125$1,274

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$200$253,411294 claims
Johnson & JohnsonXarelto$35$47,60957 claims
NovartisEntresto$187$30,86740 claims
Boehringer IngelheimJardiance$4,334$17,99829 claims
Sanofi-aventis U.S. LLCMultaq$15$10,52414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 93 clinical cardiac electrophysiology providers in Georgia.

Other clinical cardiac electrophysiology in Fort Oglethorpe

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →